Table 2.

Correlations of the fold changes in HNMT protein expression with the clinical features of patients with BC

Parameter	n	Low expression (#)	High expression (#)	χ2	P value
		Mean (§) (n%)	Mean (§) (n%)
Age				1.181	0.208
< 55 years	111	97.15 (53.2%)	234.53 (46.8%)
≥ 55 years	86	106.75 ()45.3%	234.43 (54.7%)
ER status				1.845	0.174
Negative	71	99.83 (43.7%)	245.40 (56.3%)
Positive	115	102.34 (53.9%)	128.33 (46.1%)
PR status				1.377	0.241
Negative	94	100.71 (45.7%)	239.54 (54.3%)
Positive	92	102.14 (54.3%)	231.13 (45.7%)
HER2 status				18.668	< 0.001
Negative	99	100.82 (59.6%)	207.65 (40.4%)
Positive	41	119.58 (19.5%)	248.16 (80.5%)
TNBC Subtype				0.075	0.784
No	34	122.67 (75%)	233.33 (25%)
Yes	34	97.17 (93.5%)	200.00 (6.5%)
T				2.568	0.463
T1	20	107.64 (60%)	244.26 (40.0%)
T2	88	101.68 (53.4%)	236.38 (61.5%)
T3	23	107.26 (39.1%)	231.00 (60.9%)
T4	12	80.00 (41.7%)	233.33 (58.3%)
N				2.560	0.464
N0	68	106.51 (52.9%)	243.88 (47.1%)
N1	60	96.24 (48.3%)	235.89 (51.7%)
N2	7	109.49 (71.4%)	200.00 (28.6%)
N3	9	100.00 (33.3%)	218.57 (66.7%)
Metastasis				4.002	0.120
No	140	105.77 (49.3%)	237.92 (50.7%)
Yes	4	45.00 (100%)	0.00 (0.0%)
Stage				0.660	0.719
Stage I	16	107.59 (56.2%)	253.96 (43.8%)
Stage II	86	102.73 (51.2%)	237.52 (48.8%)
Stage III/V	44	104.17 (45.5%)	233.05 (54.5%)
Survival				3.347	0.048
Alive	130	104.56 (52.3%)	240.45 (47.7%)
Dead	47	91.66 (36.4%)	227.11 (63.6%)
Recurrence				1.230	0.267
No	116	107.31 (50.0%)	247.63 (50.0%)
Yes	47	85.92 (40.4%)	220.00 (59.6%)

^#BC patients were divided into two groups according to their HNMT histo-scores in the TMA (low/below average vs. high/above average)

^§Mean fold difference in HNMT protein expression in each group. The data are the means (n%). P values ​​for all the data were analyzed using Pearson's chi-square test